TrialBMC cancer2022

The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.

Tamara K Moyo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.